Surge in Buying Pressure for Diabetes Devices... Market Cap Increased by Over 2 Trillion Won in a Day

On April 14, Dexcom Inc. (DXCM), the U.S. maker of continuous glucose monitoring devices, closed at $61.71 on the New York Stock Exchange, up 6.73% from the previous day. Trading volume rose to about 8.7 million shares, and the company’s market capitalization jumped by roughly $1.7 billion (around ₩2.3 trillion) in a single day, reaching about $23.8 billion (₩32 trillion).

The rally was driven by first-quarter results that beat market expectations—revenue grew 15% and earnings per share nearly doubled—and by a reaffirmed focus on governance and margin expansion under activist shareholder pressure, including the appointment of new independent directors and the establishment of operations and innovation committees. Positive analyst reports further boosted investor sentiment: Benchmark reiterated a buy rating with a $77 price target, while Canaccord raised its target as high as $100 based on the upcoming G7 sensor and its expansion into the non-insulin type 2 diabetes market. (finance.yahoo.com)

Founded in 1999, Dexcom is a U.S. medical device company that designs, manufactures, and sells continuous glucose monitoring (CGM) systems—the G6 and G7—to measure blood glucose in real time, holding significant market share in the U.S. and Europe. With rising obesity and diabetes prevalence, expanded insurance coverage, and growing demand for data- and AI-driven disease management, Dexcom is regarded as a leading growth stock in diabetes devices, projecting more than 10% annual organic revenue growth through 2030. (stockanalysis.com)